Best of ASCO - 2014 Annual Meeting

 

Welcome

Biomarkers/Epidemiology/Outcomes

Genitourinary (Prostate) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
PMEPA1 gene isoforms to indicate disease progression in solid tumors.

Shashwat Sharad

e16580

27-year patterns in high-risk prostate cancer treatment in a racially diverse, equal-access health care setting.

Nicholas R Rocco

e16583

Association of disease prognostic model (PM) with baseline quality of life (QOL) in metastatic castration resistant prostate cancer (mCRPC).

Anna Prizment

e16579

Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D).

Dong Shen

5066

Association of radiomic features from prostate bi-parametric MRI with Decipher risk categories to predict risk for biochemical recurrence post-prostatectomy.

Lin Li

e16561

ATM loss in primary prostate cancer: Analysis of >1000 cases using a validated clinical-grade immunohistochemistry (IHC) assay.

Emmanuel S. Antonarakis

5069

Baseline genomic and circulating tumor cell (CTC) correlative data from very high-risk (VHR), localized, node-negative prostate cancer patients.

Sean Matthew McBride

e16563

Cancer driver genes in prostate cancer from young men.

Simone Maistro

e16586

Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.

Bruce J. Trock

e16575

Cell cycle progression score differentiates indolent from aggressive prostate cancer in men diagnosed by TURP.

Jack M. Cuzick

e16560

Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.

Semini Sumanasuriya

5070

Classification of prostate cancer based on clinical and omics data using neural networks techniques to improve prognostic power.

Laura Marin

e16569

Clinical outcomes and genomic analysis in patients with very high-risk clinically localized prostate cancer treated by radical prostatectomy.

Pedro Isaacsson Velho

5067

Computerized histomorphometric features of glandular architecture predict risk of biochemical recurrence following radical prostatectomy: A multisite study.

Patrick Leo

5060

Correlation between innate cytokine levels and progression in men with biochemically recurrent prostate cancer treated with intermittent hormonal therapy.

Jessica Hawley

e16554

Deep learning algorithm improves identification of men with low-risk prostate cancer using PSMA-targeted 99mTc-MIP-1404 SPECT/CT.

Alexa Meyer

e16572

Determination of AR-V7 in plasma in patients with metastatic prostate cancer using capillary Nano-immunoassay.

Alvaro Virseda

e16574

Ductal (PDC), acinar (PAC) and neuroendocrine (PNC) carcinomas of the prostate: A comparative comprehensive genomic profiling (CGP) study.

Gennady Bratslavsky

5064

Effectiveness and tolerability of depot formulations of leuprorelin acetate in real life: Analysis of 932 patients with prostate cancer from Brazil.

Carla Simone Moreira Freitas

e16552

Evolution of androgen receptor variant (ARV) profiles in serial metastatic solid and liquid biopsies in metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate/ prednisone (AA/P).

Karthik Giridhar

e16559

Evolving natural history of metastatic prostate cancer.

Nellie Nafissi

5063

Examination of the additive value of CTC biomarkers of heterogeneity (Het) and chromosomal instability to nuclear-localized (nl) AR-V7+ CTCs in prediction of poor outcomes to androgen receptor signaling inhibitor (ARSi) in metastatic castration resistant prostate cancer (mCRPC).

Howard I. Scher

5075

Expression of human leukocyte antigen-a and b2-microglobulin in prostate cancer.

Ying-Chun Shen

e16550

Family history in primary hormone therapy for prostate cancer from a community-based multi-institutional Japan-wide database.

Masaki Shiota

e16549

Identification, incidence and clinical outcomes of patients (pts) with hypermutated prostate cancer (PC).

Simon Yuen Fai Fu

5072

Impact of comorbidity and age on treatment choice among men with localized prostate cancer.

Paul F Pinsky

e16585

IMPACT of putative chemopreventative agents on prostate cancer diagnosis.

Hanan Goldberg

e16553

Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.

Iris Yeong- Fung Sheng

5071

Longitudinal prostate cancer outcomes in a racially diverse cohort of military heath care beneficiaries: 1990-2017.

Jennifer Cullen

e16581

Low dose enzalutamide in metastatic castration-resistant prostate cancer: A retrospective Caribbean study.

Vincent Vinh-Hung

e16548

MiR-1271-5p: An AR-modulatory microRNA with a distinct role in prostate cancer progression, through SND1 and MORF4L1 interaction.

Foteini Kalofonou

e16562

Multi-gene hereditary cancer testing, family history and prognosis in men with prostate cancer.

Panagiotis J. Vlachostergios

5073

Next-generation sequencing of primary prostate cancer tumors to reveal actionable opportunities for clinical management.

Daniel James Crona

e16582

NT5E expression and the immune landscape of prostate cancer (PC): An analysis from The Cancer Genome Atlas database.

Abhishek Tripathi

e16591

Outcomes of men with prostate cancer managed with active surveillance and tested with clinical cell-cycle risk score.

Behfar Ehdaie

e16566

Pilot study to enhance FDG-PET imaging of prostate cancers with the metabolic inhibitor ranolazine.

Isabel R. Schlaepfer

e16551

Predictors and rates of adverse events (AEs) among non-metastatic prostate cancer (nmPC) patients (pts) treated with bicalutamide, abiraterone, or enzalutamide following surgical/medical castration.

Anuj Shah

e16556

Prevalence of pathogenic germline variants in DNA repair by race, age, and ethnicity in men with prostate cancer.

Alexandria Mara

5062

Prostate carcinoma in African-Americans has miRNA expression and biological markers for aggressive disease.

Malhaar Agrawal

e16558

Risk of depression following prostate cancer work-up: A nationwide study.

Anne Sofie Friberg

5061

Screening of BRCA2 mutated men for detection of prostate cancer: Preliminary results from a national high volume cancer center.

Monica Zuradelli

e16567

Shared-decision making in prostate cancer with clinical decision-support.

Hermano Alexandre Lima Rocha

e16576

Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC).

Gareth Morrison

e16587

SLFN11 expression (exp) in castration-resistant prostate cancer (CRPC) patients (pts) to predict response to platinum-based chemotherapy (PLT).

Vincenza Conteduca

5065

Survival in men diagnosed with castration resistant prostate cancer: A population-based observational study in Sweden.

Markus Aly

e16555

The effect of E2F7 expression in prostate cancer on apoptosis and cell cycle of prostate cancer cells.

Ying Wang

e16568

The predictive power of free (vs. total) testosterone in aggressive prostate cancer.

Maxwell M Towe

e16570

The rate of tumor growth, g, as a biomarker for overall survival (OS) in prostate cancer (PC) in clinical trials as well as in real-world data from the Veterans Administration Medical Centers (VAMCs).

Harshraj Leuva

5074

Tumor contact length used as a biomarker to predict extracapsular extension, lymph node involvement, and biochemical recurrence.

Públio Viana

e16588

WNT activating pathway mutations confer resistance to first-line antiandrogen therapy in castration-resistant prostate cancer (CRPC).

Pedro Isaacsson Velho

5068